Sandoz delivers further sales growth

Swiss generics and biosimilars drugmaker Sandoz (SIX: SDZ) today presented its net-sales performance for the nine months and third quarter ended September 30, 2025. Sandoz does not present profit figures for the odd-numbered quarters.

For the nine months, net sales of $8,057million were up by 5% at constant currencies (CC) and in US$; up by 6% at comparable growth rates (CGR). Volume growth of 8%. Ten largest-selling medicines grew by combined 9% at CC and represented 34% of net sales

For the third quarter, net sales of $2,825 million were up by 6% at CC and by 9% in US$, respectively; up by 7% at CGR. Volume growth was 8%. Biosimilars represented more than 30% of net sales for first time